검색
Ironwood Pharmaceuticals Inc
IRWD관심 목록에 추가
4.190USD
-0.080-1.87%
종가 09-23 16:00（ET）
689.72M시가총액
6.65P/E TTM
Ironwood Pharmaceuticals Inc 정보 회사
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Ironwood Pharmaceuticals Inc 프로필
종목 코드 IRWD
회사 이름Ironwood Pharmaceuticals Inc
상장일Feb 03, 2010
CEOMccourt (Thomas A)
직원 수253
유형Ordinary Share
회계 연도 종료Feb 03
주소100 Summer Street, Suite 2300
도시BOSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02110
전화16176217722
웹사이트https://www.ironwoodpharma.com/
종목 코드 IRWD
상장일Feb 03, 2010
CEOMccourt (Thomas A)
Ironwood Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
자주 묻는 질문
Ironwood Pharmaceuticals Inc의 상위 5대 주주는 누구인가요?
Ironwood Pharmaceuticals Inc의 상위 5대 주주는 다음과 같습니다: Dr. Mark G. Currie, Ph.D.
Ironwood Pharmaceuticals Inc(IRWD)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Ironwood Pharmaceuticals Inc의 주식을 보유한 기관은 총 549곳이며, 이들이 보유한 주식의 총 가치는 약 166.41M로 전체 발행 주식의 101.09%를 차지합니다. 이는 2025Q4 대비 -30766447.00 증가한 수치입니다.